This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Celgene Identifier:
First received: February 13, 2015
Last updated: June 21, 2017
Last verified: June 2017
This study is design to explore the effect of GED-0301 on clinical and endoscopic outcome and to evaluate its safety in subjects with active Crohn's disease.

Condition Intervention Phase
Crohn Disease Drug: GED-0301 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease.

Resource links provided by NLM:

Further study details as provided by Celgene:

Primary Outcome Measures:
  • Change in SES-CD Score [ Time Frame: Week 12 ]
    The change from baseline in the Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) score at Induction Week 12.

Secondary Outcome Measures:
  • Proportion of subjects achieving a clinical remission, defined as a CDAI score < 150 at Induction Week 4 [ Time Frame: Week 4 ]
    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score < 150

  • Adverse Event (AE) [ Time Frame: Up to 97 weeks ]
    Assessed by the type, frequency and severity of adverse events, and its relationship to investigational product (IP), discontinuation due to adverse events, and clinically significant changes in vital signs, Electrocardiograms (ECGs), and/or laboratory findings.

Enrollment: 64
Actual Study Start Date: April 8, 2015
Estimated Study Completion Date: September 18, 2019
Primary Completion Date: September 6, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GED-0301 160mg QD 12 WK
GED-0301 160 mg once daily (QD) for 12 weeks
Drug: GED-0301
Experimental: GED-0301 160 mg QD 8 WK
GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
Drug: GED-0301 Drug: Placebo
Experimental: GED-0301 160 mg QD 4 WK
GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
Drug: GED-0301 Drug: Placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is a male or female who is ≥18 years at the time of signing the Informed Consent Form (ICF).
  2. Understand and voluntarily sign an Informed Consent Form (ICF) prior to conducting any study related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Diagnosis of Crohn's Disease (CD) with a duration of at least 3 months prior to screening.
  5. Diagnosis of ileitis, ileocolitis or colitis , as determined by endoscopic, radiographic or any other imaging modality (eg, magnetic resonance imaging [MRI], computed tomography [CT] scan) evaluation performed within 2 years prior to screening. Subjects with colitis restricted to the left colon will not be allowed in the trial.
  6. Active disease, defined as Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450 (range: 0 to 600) at screening.
  7. Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥ 7 at screening. Subjects with ileitis only will require Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 4
  8. Must have failed or experienced intolerance to at least one of the following:

    aminosalicylates, budesonide, systemic corticosteroids, immunosuppressants (ie, 6 mercaptopurine [6-MP], azathioprine [AZA], or methotraxate [MTX]) or tumor necrosis factor-α tumor necrosis factor-α (TNF-α) blockers (eg, infliximab, adalimumab or certolizumab) .

  9. Subjects receiving oral aminosalicylates may continue their use during the study, provided that dose has been stable for at least 2 weeks prior to screening. The dose of oral aminosalicylates must remain stable through the duration of the study or early termination from the study. If oral aminosalicylates have been recently discontinued, treatment must have been stopped at least 2 weeks prior to screening.
  10. Subjects receiving oral corticosteroids may continue their use during the Induction Phase, provided that the dose (prednisone ≤ 20 mg/day or equivalent, budesonide ≤ 9 mg/day) has been stable for 3 weeks prior to screening. If oral corticosteroids were recently discontinued, discontinuation must have been completed at least 4 weeks prior to screening. Corticosteroid doses should remain stable until the subject is eligible to start corticosteroids tapering.
  11. Subjects receiving immunosuppressants, such as , 6 mercaptopurine (6-MP), azathioprine (AZA), or methotraxate (MTX) may continue their use during the study, provided that treatment was initiated ≥ 12 weeks prior to screening. The dose of immunosuppressants must be at a stable dose for ≥ 8 weeks prior to the Baseline Visit and must remain stable through the duration of the study or early termination from the study. Subjects who discontinued immunosuppressants should have stopped them at least 8 weeks prior to screening.
  12. Must meet the following laboratory criteria:

    1. White blood cell count ≥ 3000/mm3 (≥ 3.0 X 10^9//L) and < 14,000/mm3 (< 14.0 X 10^9/L)
    2. Platelet count ≥ 100,000/mm3 (≥ 100 X 10^9/L)
    3. Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
    4. Aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) / serum glutamic-pyruvic transaminase (SGPT) ≤ 2 X upper limit of normal (ULN)
    5. Total bilirubin ≤ 2 mg/dL (≤ 34 μmol/L) unless there is a confirmed diagnosis of Gilbert's disease
    6. Hemoglobin ≥ 9 g/dL (≥ 5.6 mmol/L)
    7. Activated partial thromboplastin time (APTT) ≤ 1.5 X ULN
  13. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and the Baseline Visit. While on IP and for at least 28 days after the Early Termination Visit or the end-of-study visit (Observation Week 52 or Extension Week 24), FCBP who engage in activity in which conception is possible must use 1 of the approved contraceptive options2 described below: Option 1: Any one of the following highly effective methods: hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation (tying your tubes); or a partner with a vasectomy OR

    Option 2: Any two of the following effective methods: male or female condom PLUS one of the following additional barrier methods:

    1. diaphragm with spermicide;
    2. cervical cap with spermicide; or
    3. contraceptive sponge with spermicide
  14. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on Investigational Product (IP) and for at least 28 days after the Early Termination Visit or the end-of-study visit (Observation Week 52 or Extension Week 24).

Exclusion Criteria:

  1. Diagnosis of Crohn's colitis restricted to the left colon , ulcerative colitis (UC), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.
  2. Local manifestations of Crohn's Disease (CD) such as strictures, abscesses, fistula, short bowel syndrome or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy.
  3. Intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to screening.
  4. Subjects with an ileostomy or a colostomy.
  5. Stool positive for any enteric pathogen or C. difficile toxin at screening.
  6. History of colorectal cancer or colorectal dysplasia.
  7. Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, Adacolumn) for the treatment of CD. In addition, prior use of any of these treatment modalities for an indication other than CD within 8 weeks of screening is also excluded.
  8. Use of intravenous (IV) corticosteroids within 2 weeks of screening.
  9. Use of topical treatment with 5 aminosalicylic acid (5-ASA) or corticosteroid enemas or suppositories within 2 weeks of screening
  10. Use of antibiotic therapy for the treatment of Crohn's Disease (CD) within 3 weeks of screening.
  11. Use of cholestyramine within 3 weeks of screening.
  12. Prior treatment with more than 2 tumor necrosis factor-α (TNF-α) blockers.
  13. Prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).
  14. Use of tumor necrosis factor-α (TNF-α) blockers within 12 weeks of the screening
  15. Administration of total parenteral nutrition (TPN) within 4 weeks of screening.
  16. History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the Investigator's opinion, would prevent the subject from participation in the study.
  17. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.
  18. Pregnant or breastfeeding.
  19. History of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.
  20. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and Herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening.
  21. History of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  22. History of malignancy, except for:

    1. Treated (ie, cured) basal cell or squamous cell in situ skin carcinomas
    2. Treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years
  23. Subjects who have received any investigational drug or device within 1 months of screening.
  24. Prior treatment with GED-0301, or participation in a clinical study involving GED-0301.
  25. History of alcohol, drug, or chemical abuse within the 6 months prior to screening.
  26. Known hypersensitivity to oligonucleotides or any ingredient in the IP.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02367183

  Show 50 Study Locations
Sponsors and Collaborators
Study Director: Guillermo Rossiter, MD Celgene
  More Information

Responsible Party: Celgene Identifier: NCT02367183     History of Changes
Other Study ID Numbers: GED-0301-CD-001
Study First Received: February 13, 2015
Last Updated: June 21, 2017

Keywords provided by Celgene:
Crohn's Disease
Active Crohn's Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on August 21, 2017